6955.TW Bonraybio Co., Ltd.
- Market cap
- TWD 2.54B
- P/E
- 23.6x
- P/B
- 3.88x
- ROE
- 15.9%
- Dividend yield
- 1.27%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6955.TW undervalued?
Graham number6955.TW trades 101.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bonraybio Co., Ltd. fundamental analysis
No fundamental analysis for Bonraybio Co., Ltd. yet.
Bonraybio Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bonraybio Co., Ltd.
Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also provides consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes. In addition, the company provides X QC Reticles, X QC video tools, and X QC beads; sperm DNA fragmentation test k…
Full company profileBonraybio Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bonraybio Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 56.3M | 106M | 160M | 223M | 306M | 353M |
| Gross Profit | 39.6M | 80.6M | 120M | 175M | 239M | 274M |
| Operating Income | -38.5M | -6.64M | 21.3M | 61.0M | 100.0M | 112M |
| EBITDA | - | 11.4M | 36.6M | 80.4M | 118M | 135M |
| Net Income | -31.7M | 1.69M | 25.7M | 68.4M | 103M | 105M |
| EPS | -1.40 | 0.07 | 1.13 | 2.76 | 4.13 | 4.22 |
| Balance Sheet | ||||||
| Total Assets | 263M | 280M | 317M | 623M | 720M | 723M |
| Total Liabilities | 25.6M | 27.2M | 38.8M | 51.4M | 78.5M | 66.2M |
| Shareholders' Equity | 237M | 253M | 278M | 571M | 641M | 657M |
| Cash & Short-term Investments | 70.0M | 89.4M | 117M | 410M | 271M | 197M |
| Cash Flow | ||||||
| Operating Cash Flow | -25.1M | 12.0M | 26.9M | 80.1M | 100.0M | 69.9M |
| Capital Expenditure | 4.64M | 7.96M | 9.75M | 11.0M | 34.2M | 40.1M |
| Free Cash Flow | -29.7M | 4.02M | 17.1M | 69.1M | 65.8M | 29.7M |
| Ratios | ||||||
| ROE | -13.4% | 0.7% | 9.2% | 12.0% | 16.0% | 15.9% |
| ROA | -12.1% | 0.6% | 8.1% | 11.0% | 14.2% | 14.5% |
| Net Profit Margin | -56.3% | 1.6% | 16.1% | 30.7% | 33.5% | 29.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bonraybio Co., Ltd. dividends
- Dividend yield
- 1.27%
- Forward dividend
- 1.50 TWD
- Payout ratio
- 31.6%
- Ex-dividend date
- Mar 26, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 32.3M | 1.30 | 31.6% |
| 2024 | TWD 3.42M | 0.14 | 5.0% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1236250:1000000 on Aug 26, 2026.
Who owns Bonraybio Co., Ltd.
Ownership data of Bonraybio Co., Ltd. is not available yet.
Bonraybio Co., Ltd. company profile
- Company name
- Bonraybio Co., Ltd.
- Ticker
- 6955.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- December
- Address
- No. 118, Gongye 9th Road, Taichung, Taiwan, 41280
- Phone
- 886 4 2491 2385
- Website
- bonraybio.com
About Bonraybio Co., Ltd.
Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also provides consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes. In addition, the company provides X QC Reticles, X QC video tools, and X QC beads; sperm DNA fragmentation test kits; and S10 data consolidation software. Bonraybio Co., Ltd. was founded in 2015 and is based in Taichung, Taiwan.
Bonraybio Co., Ltd. management
3- Mr. Zhenteng XuChairman & GM
- Ms. Peizhen YangAccounting Supervisor, Deputy GM of Admin and Head of Corporate Governance & Information Security
- Mr. Yingzhi LiaoExecutive VP and Head of R&D